DATA SHEET XYNTHA - Medsafe
DATA SHEET XYNTHA ® moroctocog alfa (rch) (recombinant coagulation factor VIII) NAME OF THE MEDICINE XYNTHA moroctocog alfa (rch) 250, 500, 1000, 2000 IU powder for injection vial.
Download DATA SHEET XYNTHA - Medsafe
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
The Complete list of NANDA Nursing Diagnosis for …
www.kc-courses.comThe Complete list of NANDA Nursing Diagnosis for 2012-2014, with 16 new diagnoses. Below is the list of the 16 new NANDA Nursing Diagnoses 1. …
LWBK942-FM.qxd 6/25/11 8:45 AM Page x
www.damanhour.edu.eg1 1 Medical-surgical nurses are the backbone of health and wellness care in the United States. Indeed, new nurs-ing graduates are strongly encouraged to work in a hospital as a medical-surgical nurse for 1 to 2 years to
Getting Started Kit - Canadian Patient Safety Institute
www.patientsafetyinstitute.caSafer Healthcare Now! Prevent Surgical Site Infections Getting Started Kit Safer Healthcare Now! We invite you to join Safer Healthcare Now! to help improve the safety of the Canadian healthcare system. Safer Healthcare Now!the flagship program of the Canadian Patient is Safety Institute and a national program supporting Canadian …
ANXIETY QUESTIONNAIRE TO BE COMPLETED BY …
www.abaoms.org.ukIndicator of Sedation Need (IOSN) MATRIX TO BE COMPLETED BY THE DENTIST SEDATION NEED domain 1 + 2 + 3 scores Total Rank Score Source Descriptor Sedation Need 3-4 Minimal need No
Drug Therapy Trastuzumab — Mechanism of …
www.cellbiol.netThe new engl and journal of medicine n engl j med 357;1 www.nejm.org july 5, 2007 39 Drug Therapy Trastuzumab — Mechanism of Action and Use in Clinical Practice Clifford A. Hudis, M.D.
Drug, Therapy, Action, Mechanisms, Drug therapy trastuzumab mechanism of, Trastuzumab, Drug therapy trastuzumab mechanism of action